Moxifloxacin versus levofloxacin against acute exacerbations of chronic bronchitis: the Latin American Cohort

dc.contributor.authorUrueta-Robledo, Juan
dc.contributor.authorAriza, Horacio
dc.contributor.authorJardim, José Roberto [UNIFESP]
dc.contributor.authorCaballero, Andres
dc.contributor.authorGarcia-Calderon, Andres
dc.contributor.authorAmabile-Cuevas, Carlos F.
dc.contributor.authorHernandez-Oliva, Gerardo
dc.contributor.authorVivar-Orozco, Raul
dc.contributor.authorMOX-CB Study Group
dc.contributor.institutionFdn LUSARA
dc.contributor.institutionInst Nacl Enfermedades Resp
dc.contributor.institutionHosp Mi Pueblo
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.contributor.institutionClin Reina Sofia
dc.contributor.institutionClin Ricardo Palma
dc.contributor.institutionBayer Mexico
dc.description.abstractWe compared the efficacy and safety of moxifloxacin and levofloxacin for the treatment of patients with acute exacerbations of chronic bronchitis (AECB) using a prospective, randomized, double blind, parallel-group clinical trial design. A total of 563 patients with AECB were enrolled (437 efficacy-valid) at 34 centers in Mexico, Argentina, Brazil, Colombia, and Peru. Patients were randomized to oral therapy with either moxifloxacin 400 mg once daily for 5 days or levofloxacin 500 mg once daily for 7 days. Clinical success was achieved in 201 out of 221 (91.0%) patients in the moxifloxacin group, and in 203 out of 216 (94.0%) in the levofloxacin group, indicating that moxifloxacin is equivalently effective to levofloxacin. Bacteriologic eradication or presumed eradication was also similar in the two treatment groups: 92.8% in the moxifloxacin group and 93.8% in the levofloxacin group. Nausea was the most common drug-related adverse event in each treatment group. the rate of discontinuation because of adverse events was very low (<= 2%). in conclusion, a 5-day course of moxifloxacin is clinically and bacteriologically equivalent to a 7-day course of levofloxacin in the treatment of patients with AECB. the short treatment duration with moxifloxacin may have compliance advantages over other currently used therapies in the 'real-Life' clinical setting. (c) 2006 Elsevier B.V. All rights reserved.en
dc.description.affiliationFdn LUSARA, Mexico City 08930, DF, Mexico
dc.description.affiliationInst Nacl Enfermedades Resp, Mexico City, DF, Mexico
dc.description.affiliationHosp Mi Pueblo, Buenos Aires, DF, Argentina
dc.description.affiliationUniversidade Federal de São Paulo, São Paulo, Brazil
dc.description.affiliationClin Reina Sofia, Bogota, Colombia
dc.description.affiliationClin Ricardo Palma, Lima, Peru
dc.description.affiliationBayer Mexico, SA & CV, Mexico City, DF, Mexico
dc.description.affiliationUnifespUniversidade Federal de São Paulo, São Paulo, Brazil
dc.description.sourceWeb of Science
dc.identifier.citationRespiratory Medicine. London: W B Saunders Co Ltd, v. 100, n. 9, p. 1504-1511, 2006.
dc.publisherW B Saunders Co Ltd
dc.relation.ispartofRespiratory Medicine
dc.rightsAcesso aberto
dc.subjectchronic bronchitisen
dc.titleMoxifloxacin versus levofloxacin against acute exacerbations of chronic bronchitis: the Latin American Cohorten
Pacote Original
Agora exibindo 1 - 1 de 1
Imagem de Miniatura
100.57 KB
Adobe Portable Document Format